As mergers and acquisitions (M&A) in life sciences continue to make news headlines across the globe, we thought it would be interesting to share insights on this topical issue from Deloitte's U.S. Center for Health Solutions. This “My Take” from the August 19, 2014 Health Care Current written by Homi Kapadia, Vice Chairman, U.S Life Sciences Leader, Deloitte LLP, provides a road map of key questions that might be considered by companies seeking to transform their business through acquisitions, divestitures, or joint ventures. It also poses the question, "What will Congress do?” to pass legislation that makes these kinds of deals less attractive and encourage firms to stay in the U.S.[i]
Knee replacements are the most common joint replacement operation in Britain, with 90,000 performed each year. A few months ago I had a total knee replacement (TKR) operation in an attempt to relieve the pain and improve mobility of the joint, which had become seriously arthritic following a hockey injury several years ago.
The theme of the World Health Day in April 2014 was vector-borne diseases- ‘Small Bite: Big Threat’. For many people this conjured up thoughts of Malaria, Dengue or West Nile Virus but, few people in the UK are aware that the UK’s most common vector-borne human infection is Lyme disease.[i]
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our regulatory compliance specialists in health care and life sciences:
Off-label prescribing is the prescription of a drug for an indication or for an age group, dose or form of administration for which it is not approved. Recently, it has become a thorny topic for the life sciences industry, regulators and healthcare payers, with high profile cases arising in France and Italy.
In one of our previous blogs we discussed the US Food and Drug Administration’s (FDA’s) introduction of the ‘breakthrough’ designation concept as a way of improving earlier access to medicines for patients with high unmet medical need. In this blog we’re focussing on the Early Access to Medicines Scheme (EAMS), a similar scheme launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2014.
Last week we held our third roundtable discussion on the Deloitte Centre for Health Solution’s report on better care for frail older people.
Wearable technology is an industry that continues to grow and adapt to meet the ever-changing needs of our world. Many health- and fitness-related technologies have multiple applications and encourage wearers to be more engaged in their own fitness, help modify behavior by reminding wearers to exercise or take medication.
As our recent report Better care for frail older people identified: healthcare continues to face enormous cost and capacity challenges; largely as a result of increasing demand from growing numbers of older people with multiple complex conditions and a rise in the incidence of non-communicable diseases such as diabetes, cancer and obesity.
One of the key challenges for life science research and development (R&D) is identifying which biochemical pathways and diseases to target. Given the average cost of bringing a new drug to market is now an estimated $1.3 billion dollars as revealed in our 2013 R&D ROI report, it’s clear that R&D leaders are looking to maximise their returns. However, it is also becoming increasingly clear that only those drugs that deliver additional patient benefits will gain approval and funding.
Across the UK, prostate cancer kills one man every hour (or 10,636 every year) and is the most common cancer in men. Indeed, 40,000 men are diagnosed with prostate cancer every year and currently there are 255,000 men living with and after the disease.[i] In the UK prostate cancer survival rates are below the European average and quality of care can depend on where you live.